162 related articles for article (PubMed ID: 20543821)
1. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.
Lambros MB; Natrajan R; Geyer FC; Lopez-Garcia MA; Dedes KJ; Savage K; Lacroix-Triki M; Jones RL; Lord CJ; Linardopoulos S; Ashworth A; Reis-Filho JS
Mod Pathol; 2010 Oct; 23(10):1334-45. PubMed ID: 20543821
[TBL] [Abstract][Full Text] [Related]
2. Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study.
Dedes KJ; Lopez-Garcia MA; Geyer FC; Lambros MB; Savage K; Vatcheva R; Wilkerson P; Wetterskog D; Lacroix-Triki M; Natrajan R; Reis-Filho JS
Breast Cancer Res Treat; 2010 Dec; 124(3):653-66. PubMed ID: 20213079
[TBL] [Abstract][Full Text] [Related]
3. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
Arriola E; Marchio C; Tan DS; Drury SC; Lambros MB; Natrajan R; Rodriguez-Pinilla SM; Mackay A; Tamber N; Fenwick K; Jones C; Dowsett M; Ashworth A; Reis-Filho JS
Lab Invest; 2008 May; 88(5):491-503. PubMed ID: 18332872
[TBL] [Abstract][Full Text] [Related]
5. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23.
Li J; Yang Y; Peng Y; Austin RJ; van Eyndhoven WG; Nguyen KC; Gabriele T; McCurrach ME; Marks JR; Hoey T; Lowe SW; Powers S
Nat Genet; 2002 Jun; 31(2):133-4. PubMed ID: 12021784
[TBL] [Abstract][Full Text] [Related]
7. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
[TBL] [Abstract][Full Text] [Related]
8. Identification of differentially expressed genes after PPM1D silencing in breast cancer.
Pärssinen J; Alarmo EL; Khan S; Karhu R; Vihinen M; Kallioniemi A
Cancer Lett; 2008 Jan; 259(1):61-70. PubMed ID: 17977650
[TBL] [Abstract][Full Text] [Related]
9. Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
Natrajan R; Lambros MB; Rodríguez-Pinilla SM; Moreno-Bueno G; Tan DS; Marchió C; Vatcheva R; Rayter S; Mahler-Araujo B; Fulford LG; Hungermann D; Mackay A; Grigoriadis A; Fenwick K; Tamber N; Hardisson D; Tutt A; Palacios J; Lord CJ; Buerger H; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(8):2711-22. PubMed ID: 19318498
[TBL] [Abstract][Full Text] [Related]
10. Protein phosphatase magnesium-dependent 1δ (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma.
Li GB; Zhang XL; Yuan L; Jiao QQ; Liu DJ; Liu J
PLoS One; 2013; 8(3):e60775. PubMed ID: 23556002
[TBL] [Abstract][Full Text] [Related]
11. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
[TBL] [Abstract][Full Text] [Related]
13. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A
Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
[TBL] [Abstract][Full Text] [Related]
15. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
Elsheikh S; Green AR; Aleskandarany MA; Grainge M; Paish CE; Lambros MB; Reis-Filho JS; Ellis IO
Breast Cancer Res Treat; 2008 May; 109(2):325-35. PubMed ID: 17653856
[TBL] [Abstract][Full Text] [Related]
16. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
Fasching PA; Weihbrecht S; Haeberle L; Gasparyan A; Villalobos IE; Ma Y; Ekici AB; Wachter DL; Hartmann A; Beckmann MW; Slamon DJ; Press MF
Breast Cancer Res Treat; 2014 May; 145(1):193-203. PubMed ID: 24682655
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
[TBL] [Abstract][Full Text] [Related]
18. PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Yang H; Gao XY; Li P; Jiang TS
Tumour Biol; 2015 Mar; 36(3):2179-84. PubMed ID: 25412952
[TBL] [Abstract][Full Text] [Related]
19. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
Zhang M; Xu E; Zhang J; Chen X
Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
[TBL] [Abstract][Full Text] [Related]
20. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.
Reis-Filho JS; Milanezi F; Carvalho S; Simpson PT; Steele D; Savage K; Lambros MB; Pereira EM; Nesland JM; Lakhani SR; Schmitt FC
Breast Cancer Res; 2005; 7(6):R1028-35. PubMed ID: 16280056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]